# Rezolute, Inc.: overview RZLT · Nasdaq · CIK 1509261 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/rzlt.md) · [Financials](/companies/rzlt/financials.md) · [Filings](/companies/rzlt/filings.md) · [Insiders](/companies/rzlt/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.22)](/filings/0001104659-25-107781.md) | [(0.22)](/filings/0001104659-26-014334.md) | [(0.27)](/filings/0001104659-26-059422.md) | not reported | [(0.18)](/filings/0001104659-25-107781.md) | [(0.22)](/filings/0001104659-26-014334.md) | [(0.16)](/filings/0001104659-26-059422.md) | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.32)](/filings/0001558370-23-015755.md) | [(1.01)](/filings/0001558370-24-012901.md) | [(1.33)](/filings/0001104659-25-090848.md) | [(0.98)](/filings/0001104659-26-110420.md) | [(0.75)](/filings/0001104659-26-110420.md) | | Free cash flow | $m | not reported | [(44.6)](/filings/0001558370-24-012901.md) | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rzlt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $67.6m | 12,990,659 | | Unchanged | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $49.1m | 9,445,039 | | Added +265,039 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $40.1m | 7,718,291 | | Added +1,404,788 | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $32.8m | 6,300,000 | | Unchanged | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $24.2m | 4,662,039 | | Reduced −386,382 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $19.9m | 3,835,827 | | Added +313,747 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $17.3m | 3,328,287 | | Unchanged | | [JACOBS LEVY EQUITY MANAGEMENT, INC](/funds/884414.md) | 2026-06-30 | $13.3m | 2,561,654 | | Added +2,341,247 | | [JENNISON ASSOCIATES LLC](/funds/53417.md) | 2026-06-30 | $12.8m | 2,459,308 | | Reduced −979,573 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $11.3m | 2,170,154 | | Added +205,795 | ## Recent filings [All 745 filings](/companies/rzlt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 16:47 ET | [DEF 14A](/filings/0001104659-26-117868.md) | Proxy statement, period 2026-12-02 | 0001104659-26-117868 | | 2026-10-14 | 17:11 ET | [8-K](/filings/0001104659-26-115874.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-115874 | | 2026-10-05 | 08:00 ET | [8-K](/filings/0001104659-26-113503.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-113503 | | 2026-09-24 | 16:24 ET | [10-K](/filings/0001104659-26-110420.md) | Annual report, period 2026-06-30 | 0001104659-26-110420 | | 2026-09-24 | 16:16 ET | [8-K](/filings/0001104659-26-110412.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-110412 | | 2026-06-02 | 07:05 ET | [8-K](/filings/0001104659-26-069206.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-069206 | | 2026-05-12 | 16:20 ET | [10-Q](/filings/0001104659-26-059422.md) | Quarterly report, period 2026-03-31 | 0001104659-26-059422 | | 2026-05-12 | 16:10 ET | [8-K](/filings/0001104659-26-059392.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-059392 | | 2026-05-04 | 16:30 ET | [8-K](/filings/0001104659-26-054943.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-054943 | | 2026-03-24 | 07:30 ET | [8-K](/filings/0001104659-26-033592.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-033592 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001104659-26-110420.md), filed Sep 24, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1509261 - Tickers: RZLT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:16 ET. No prices; not investment advice.